A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.
Kura Oncology, Inc.
Bristol-Myers Squibb
Mirati Therapeutics Inc.
Incyte Corporation
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.